AlzeCure Pharma
STOCKHOLM, SE / ACCESSWIRE / October 11, 2021 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6)
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announced that the company is participating at Redeye Neurology (CNS) Seminar on October 13 at 10:55 CEST, where CSO Johan Sandin will present the company's latest developments. The presentation will be followed by a panel discussion together with representatives from AlziNova and BioArctic and moderated by Redeye's analysts.
The presentation will be held in English and live streamed via https://www.redeye.se/events/815803/neurology-seminar-cns-3 . The presentation will also be available afterwards on AlzeCure's website https://www.alzecurepharma.se/en/presentations-and-interviews/ .
For more information, please contact
Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com
About AlzeCure Pharma AB (publ)
AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.
NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development to an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.
FNCA Sweden AB, +46(0)8 528 00 399 info@fnca.se, is the company's Certified Adviser. For more information, please visit www.alzecurepharma.se.
Image Attachments
Johan Sandin CSO AlzeCure Pharma
Attachments
AlzeCure presents at Redeye Neurology (CNS) Seminar on October 13
SOURCE: AlzeCure Pharma
View source version on accesswire.com:
https://www.accesswire.com/667525/AlzeCure-Presents-at-Redeye-Neurology-CNS-Seminar-on-October-13
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
A New Shade of Comfort: LiberNovo Omni Debuts New Moss Green Design6.1.2026 08:10:00 CET | Press release
HONG KONG, HK / ACCESS Newswire / January 6, 2026 / LiberNovo The pioneer of dynamic ergonomic seating today announced the upcoming Moss Green variant of its flagship chair, the LiberNovo Omni , launching in Europe on January 17, 2026 (CET) . Building on the success of Midnight Black and Space Grey, Moss Green introduces a nature-inspired palette paired with a softer, upgraded fabric designed for long-hour comfort. As hybrid work becomes the norm across Europe, professionals increasingly seek seating that integrates seamlessly into home environments while supporting extended periods of task switching. Moss Green offers a warm, understated aesthetic that blends naturally into modern workspaces. The new colorway retains the LiberNovo Omni's full Dynamic Support system, providing adaptive support whether users are deeply focused, shifting between tasks, or relaxing after long sessions. A Calming Revival of Nature, Designed for Modern Work Inspired by forest moss, the Moss Green tone blend
Datavault AI and Available Infrastructure to Scale Physical Private Edge Cloud to Deliver Powerful Zero Trust Cybersecurity, Digital Twin and Agentic Data Monetization to 100 U.S. Cities in 20265.1.2026 14:07:00 CET | Press release
Partnership pairs Datavault AI's patented DataValue®, DataScore® and Information Data Exchange® (IDE®) solutions with Available Infrastructure's SanQtum™ cybersecure high performance points of presence designed to support near-real-time tokenization, data exchange, and agentic monetization that will provide Datavault AI the foundation to scale enterprise adoption of its AI while also solving for requisite regulatory compliance for its IDE® Quantum Key Encryption from SanQtum will further differentiate patented and forthcoming Datavault AI IDE deployments with Elements Exchange (RWA), NIL and American Political Exchanges set to Launch Q1 2026, that will be quantum ready 33 Top cities in US will begin with systems integration of patented Data Vault, DataScore, IDE and Available Infrastructure's SanQtum cybersecurity for private high performance computing in the Datavault AI Edge Network PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 5, 2026 / Datavault AI ("Datavault AI" or the "
Datavault AI and The Dream Bowl to Set New Benchmark in Sports Innovation with World’s First Tokenized Autograph Session, Featuring Current and Future NFL Stars - Live on ESPN+2.1.2026 19:50:00 CET | Press release
30 former NFL star players from different NFL Teams will autograph on-site up to 3,000 The Dream Bowl memorabilia items such as helmets, footballs, jerseys, and live-autographs by Notable Live. Autographed memorabilia items will be anchored by Prova & Sumerian technologies and digital twins will be tokenized with Data Vault. Digital tokens anchored to real The Dream Bowl autographed memorabilia items will be awarded [by lottery] to holders of the original Dream Bowl Meme Coin token (the "Dream Bowl Meme Coin I") and, following the distribution date of the Dream Bowl Meme Coin II tokens to certain record holders of Datavault AI securities as of January 7, 2026 (the "Dream Bowl Meme Coin II" and together with the Dream Bowl Meme Coin I, the "Dream Bowl Meme Coins"), to holders of the Dream Bowl Meme Coin II, throughout 2026 with an average of 10 winners selected every business day. Dream Bowl Meme Coins memorabilia digital tokens will be traded on Datavault AI's forthcoming International
Clean Air Metals Files Interim Financial Statements for the Nine Months Ended October 31, 202530.12.2025 03:20:00 CET | Press release
THUNDER BAY, ON / ACCESS Newswire / December 29, 2025 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSXV:AIR)(FRA:CKU)(OTCQB:CLRMF) announces that it has filed its unaudited consolidated interim financial statements and management's discussion and analysis for the nine-month period ended October 31, 2025, available for viewing on www.sedarplus.ca. Financial Highlights Total assets as at October 31, 2025 of $36,602,553 Total cash as at October 31, 2025 of $1,643,422 Working capital deficiency as at October 31, 2025 of $1,746,454 Shareholder's equity as at October 31, 2025 of $33,030,843 During the nine months ended October 31, 2025, the Company incurred $1,046,223 in cost for exploration activities at the TBN project. Key activities of the Company's management team this quarter included the completion of the initial drilling of the first step-out exploration target within the Escape down-plunge area, resulting in a mineralized intersection 400m from the known resource.
EESystem Files for Preliminary Injunction to Block Unauthorized Use of Proprietary Wellness Technology29.12.2025 17:15:00 CET | Press release
Legal action seeks to halt Jason Shurka and The Light System, Inc. from misappropriating EES intellectual property LAS VEGAS, NV / ACCESS Newswire / December 29, 2025 / Energy Enhancement System, LLC (EES), a global provider of advanced wellness technology, has taken decisive legal action to protect its proprietary innovations and the integrity of its licensed network. On December 22, 2025, EES filed a Motion for Preliminary Injunction in the U.S. District Court for the District of Nevada. The motion seeks to immediately enjoin defendants Jason Shurka and The Light System, Inc., operating via thelightsystems.com and unifydhealing.com, with events and personal bio promoted on jasonshurka.com, from the unauthorized use of EES's intellectual property. This filing is a critical step in defending the authenticity of the EE System technology, which powers an extensive global network with thousands of installations worldwide. The motion is supported by detailed evidence alleging contractual b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom